NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Inclusion Criteria: * Patients must have histologically confirmed Kaposi sarcoma * Patients must have evaluable disease. Note: Kaposi sarcoma will be evaluated using a modified version (consistent with National Cancer Institute \[NCI\] studies) of the Acquired Immunodeficiency Syndrome (AIDS) Clinical Trial Group (ACTG) Oncology Committee staging and response definitions for KS * No upper or lower limit on the number of prior therapies or stage of disease * HIV-positive patients must have been on effective anti-retroviral (ART) therapy for at least 3 months prior to enrollment, with persistent KS affecting quality of life due to either T1 disease or T0 disease with inadequate disease regression on ART alone * HIV-positive patients must have undetectable HIV viral loads =\< 40 copies/mL measured using a Food and Drug Administration (FDA)-approved commercial assay with lower limit of detection between =\< 20 copies/mL and =\< 40 copies/mL * Patients with visceral involvement must: * Meet other eligibility criteria * Have any/all associated tumor associated symptoms =\< grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) criteria; and/or * Require no immediate intervention (e.g. mild oozing of oral KS not an exclusion criteria) * Patients must provide newly obtained core, punch, or excisional biopsy of a tumor lesion obtained up to 28 days prior to treatment initiation. An archival tumor sample obtained within 1 year of screening is allowed if pre treatment…